A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

What Was Tested

This registered phase 3 trial tested Insulin Glargine.

It had two arms (groups): Insulin Efsitora Alfa (experimental) and Insulin Glargine (active comparator).

The registry classes the interventions as drug.

Who Took Part

Enrollment: 795 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a diagnosis of T2D according to the World Health Organization criteria. Are insulin naive. Short-term insulin treatment for a maximum of 14 days, prior to screening, and. Prior insulin treatment for gestational diabetes.

The full record lists 6 inclusion and 10 exclusion criteria; among the exclusions: have a history of \>1 episode of ketoacidosis or hyperosmolar state or coma requiring hospitalization within 6 months prior to screening; have had severe hypoglycemia episodes within 6 months prior to screening; have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with the measurement of hba1c.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

The Insulin Glargine group and the comparison group ran side by side rather than switching.

Being open-label, the Insulin Glargine study did not mask who received what.

It started in 2023-01-14 with completion listed for 2024-07-19.

It ran at 71 sites in United States (39), Argentina (21), Mexico (9) and Puerto Rico (2).

Its stated primary purpose is treatment.

What Was Measured

It also tracked 13 secondary outcomes, for example Change From Baseline in Fasting Glucose, Rate Per Year of Hypoglycemia Events, Percentage of Participants With Hypoglycemia Events (Incidence), Rate Per Year of Nocturnal Hypoglycemia Events, Percentage of Participants With Nocturnal Hypoglycemia Events (Incidence) and Change From Baseline in Body Weight.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Insulin Glargine in 795 people.

With 795 participants it is a large trial for this field.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Insulin Glargine compound page, all human trials.